U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07751315) titled 'A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases' on July 23.
Brief Summary: This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjogren's syndrome, designed to evalu...